Please assess the completion status of the following clinical trial:

Trial Title: Study of Pemetrexed Versus Pemetrexed Plus Erlotinib as Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Histological or cytological diagnosis of locally advanced or metastatic NSCLC that is of nonsquamous histology and not amenable to curative therapy.~* Failure of previous treatment with one prior platinum-based chemotherapy regimen.~* Good performance status.~* Adequate bone marrow reserve, renal and hepatic functions.~Exclusion Criteria:~* Serious concomitant systemic disease.~* Inability to take oral medication.~* Inability or unwillingness to take vitamin supplementation and corticosteroids.~* Pregnancy / Breast-feeding.~* Treatment with certain medicines that prevent blood from clotting.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pemetrexed (Nonsquamous) (Type: EXPERIMENTAL): Group of participants with non-small cell lung cancer (NSCLC) of nonsquamous histology who were assigned to Pemetrexed arm
- Pemetrexed + Erlotinib (Nonsquamous) (Type: EXPERIMENTAL): Group of participants with NSCLC of nonsquamous histology who were assigned to Pemetrexed + Erlotinib arm
- Pemetrexed (Squamous) (Type: EXPERIMENTAL): Group of participants with NSCLC of squamous histology who were assigned to Pemetrexed arm
- Pemetrexed + Erlotinib (Squamous) (Type: EXPERIMENTAL): Group of participants with NSCLC of squamous histology who were assigned to Pemetrexed + Erlotinib arm

Based on this trial design, predict the completion outcome and termination type (if applicable).